SCHEMBL4124228

SCHEMBL4124228

COc1c(F)cccc1C(O)c1cc(Cl)ccc1NC(=O)O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LPAR1 Q92633 4/20 0.43
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RECQL P46063 1/20 0.39
ALDH1A1 P00352 4/20 0.39
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
TAS1R2 Q8TE23 2/20 0.38
KMT2A Q03164 3/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM4E B2RXH2 1/20 0.37
GRIK1 P39086 1/20 0.36
PKM P14618 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116747 0.88 LPAR1 (0.45) LPAR1LMNASMN1; SMN2RECQLALDH1A1
SCHEMBL4124330 0.86 LPAR1 (0.40) LPAR1ALDH1A1TAS1R3TAS1R1TAS1R2
SCHEMBL4125981 0.86 KMT2A (0.42) LPAR1LMNASMN1; SMN2RECQLALDH1A1
SCHEMBL4129998 0.84 LPAR1 (0.48) LPAR1LMNASMN1; SMN2ALDH1A1KMT2A
SCHEMBL4124875 0.83 LPAR1 (0.45) LPAR1LMNASMN1; SMN2ALDH1A1KMT2A
SCHEMBL4122916 0.82 LPAR1 (0.56) LPAR1LMNASMN1; SMN2ALDH1A1KMT2A
SCHEMBL4123090 0.81 LPAR1 (0.50) LPAR1LMNASMN1; SMN2ALDH1A1KMT2A
SCHEMBL4125868 0.81 LPAR1 (0.50) LPAR1LMNASMN1; SMN2ALDH1A1KMT2A
SCHEMBL4118297 0.81 LPAR1 (0.49) LPAR1LMNAALDH1A1KMT2APOLB
SCHEMBL4134040 0.79 LPAR1 (0.49) LPAR1LMNASMN1; SMN2RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR LPAR1 345/4885LMNA 1109/4885SMN1; SMN2 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.